IC Targets AS
🇳🇴Norway
- Country
- 🇳🇴Norway
- Ownership
- Private
- Established
- 2002-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.ictargets.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients.
Phase 2
Recruiting
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFPEF)
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- IC TARGETS AS
- Target Recruit Count
- 42
- Registration Number
- NCT06731738
- Locations
- 🇳🇴
Oslo University Hospital, Department of Cardiology, Rikshospitalet Sognsvannsveien 20, Oslo, Norway
News
No news found